ReviewJournal of fish diseases2026
Innovative Field Applications of Probiotics, Prebiotics, and Medicinal Plant Products for Disease Control in Aquaculture.
Review in Journal of fish diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanotechnology-Based Immunostimulants in Aquaculture: Mechanisms, Advances and Practical Applications.Veterinary medicine and science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disease outbreaks and the associated reliance on antibiotics pose major constraints to the sustainability of modern aquaculture. As regulatory pressures increase and consumer demand shifts toward residue-free production, diverse biological interventions are gaining prominence as viable alternatives to chemotherapeutics. These include microbiome-modulating agents (probiotics, classical prebiotics, and synbiotics), alongside a distinctly separate category of functional additives: phytogenics (medicinal plant derivatives), which are valued for their direct bioactive and immunomodulatory properties. This review synthesizes current laboratory and field-based evidence regarding the efficacy, mechanisms, and practical challenges of these functional additives. While in vitro and controlled studies demonstrate clear benefits in immune modulation, competitive exclusion, and gut health, real-world application is frequently hindered by environmental inconsistencies and formulation instability. We critically evaluate the impact of system-specific variables and draw several specific mechanistic inferences: First, the over-reliance on static in vitro assays fundamentally fails to predict in vivo colonization under multifactorial field stress (e.g., thermal and pH fluctuations). Second, thermal degradation during industrial feed extrusion is a primary driver of batch-to-batch inconsistency, rendering advanced microencapsulation and post-coating techniques practically mandatory for viable delivery. Third, the efficacy of functional additives is strictly governed by the culture matrix; while the chemical stability of Recirculating Aquaculture Systems (RAS) yields predictable outcomes, open ponds face severe abiotic fluctuations, and Biofloc Technology (BFT) requires precise Carbon-to-Nitrogen (C:N) stoichiometry to facilitate heterotrophic assimilation. To overcome these limitations, we propose a strategic shift toward next-generation interventions specifically thermal-stable postbiotics, precision phage therapy for niche-clearing, and rigorous multi-omics technologies for molecular validation, replacing purely phenotypic observations. By integrating these specific innovations within a precision digital health framework, this work provides a comprehensive roadmap for standardizing bio-based disease control for sustainable and reproducible aquaculture production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.